Form 4: Equillium Director Mark Pruzanski Receives Stock Options

Equillium, Inc. director Mark Pruzanski was granted 70,000 stock options as part of his compensation package.

Summary

• Director Mark Pruzanski was granted 70,000 stock options to purchase common stock in Equillium, Inc.
• The options have an exercise price of $2.84 per share.
• The grant date for these options is May 28, 2026.
• The options are set to expire on May 27, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The issuance of stock options results in potential future dilution for existing shareholders.

Risks

• Market volatility affecting the value of the underlying common stock relative to the $2.84 exercise price.

Future Outlook

The options vest in twelve equal monthly installments starting May 28, 2026, with full vesting guaranteed by the date of the next annual stockholders meeting.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard practice in the biotechnology sector to incentivize board members and align their interests with corporate performance milestones.

Comparison to Industry Standards

• The use of monthly vesting schedules is consistent with standard corporate governance practices for non-employee directors in small-cap biotech firms.

Stakeholder Impact

• Minor potential dilution for existing shareholders upon future exercise of options.

Next Steps

• Vesting of options over the next twelve months.

Key Dates

Keywords

Equillium, EQ, Form 4, Insider Trading, Stock Options, Director Compensation